目的 基于網(wǎng)絡(luò)藥理學(xué)方法探討麻杏石甘湯的主要活性成分及治療支氣管哮喘的作用機(jī)制。方法 在中藥系統(tǒng)藥理學(xué)分析平臺(tái)（TCMSP）數(shù)據(jù)庫(kù)中檢索麻杏石甘湯的化學(xué)成分及靶點(diǎn)，采用Cytoscape 3.7.2軟件構(gòu)建活性成分-預(yù)測(cè)靶點(diǎn)網(wǎng)絡(luò)圖。在Genecards數(shù)據(jù)庫(kù)中獲取支氣管哮喘疾病靶點(diǎn)，與藥物靶點(diǎn)映射獲得麻杏石甘湯作用于支氣管哮喘的預(yù)測(cè)靶點(diǎn)。通過(guò)STRING數(shù)據(jù)庫(kù)構(gòu)建靶點(diǎn)相互作用網(wǎng)絡(luò)，導(dǎo)入Cytoscape 3.7.2中篩選麻杏石甘湯的核心靶點(diǎn)。利用DAVID數(shù)據(jù)庫(kù)及Cytoscape3.7.2對(duì)麻杏石甘湯的核心靶點(diǎn)進(jìn)行KEGG信號(hào)通路和GO生物過(guò)程富集分析，并構(gòu)建麻杏石甘湯活性成分-核心靶點(diǎn)-信號(hào)通路網(wǎng)絡(luò)圖。結(jié)果 預(yù)測(cè)結(jié)果顯示，麻杏石甘湯中136個(gè)主成分可靶向98個(gè)哮喘相關(guān)靶點(diǎn)，關(guān)鍵有效成分包括麻黃堿、槲皮素、木犀草素、山柰酚等，核心靶點(diǎn)包括IL-6、MAPK3、TNF、TP53、VEGFA、JUN、EGFR、EGF、NOS3、CAT，涉及HIF-1、PI3K-Akt、MAPK、雌激素等71個(gè)信號(hào)通路和RNA聚合酶II啟動(dòng)子轉(zhuǎn)錄、細(xì)胞凋亡過(guò)程、ERK1和ERK2級(jí)聯(lián)的正調(diào)控、上皮細(xì)胞增殖、平滑肌細(xì)胞增殖等20個(gè)生物過(guò)程。結(jié)論 初步揭示了麻杏石甘湯的藥效物質(zhì)基礎(chǔ)及治療支氣管哮喘的機(jī)制，為麻杏石甘湯治療支氣管哮喘的研究提供參考。

Objective To explore the active components and mechanism of Maxing Shigan Decoction in the treatment of bronchial asthma by network pharmacology. Methods Firstly, the components of Maxing Shigan decoction were searched through the Chinese Medicine System Pharmacology (TCMSP) database. Cytoscape 3.7.2 was used to build a network between components and targets. Bronchial asthma disease targets were obtained in Genecards database, then mapped with drug targets to obtain the predicted targets of Maxing Shigan Decoction for bronchial asthma. The target interaction network was constructed through the STRING database and imported into Cytoscape 3.7.2 to screen the core targets of Maxing Shigan Decoction. Finally, DAVID database and Cytoscape 3.7.2 were used to perform KEGG pathway enrichment analysis and GO biological process enrichment analysis, and build active ingredients-key targets-KEGG pathway network map. Results Network pharmacological analysis shows that 136 main components in MaXing Shigan Decoction correspond to 98 asthma targets. The key active ingredients include ephedrine, quercetin, luteolin, kaempferol, etc. The core targets include:IL-6, MAPK3, TNF, TP53, VEGFA, JUN, EGFR, EGF, NOS3, CAT. KEGG signaling pathway analysis obtained 68 signaling pathways, mainly related to:HIF-1、PI3K-Akt、MAPK and Estrogen signaling pathway, etc. GO biological process analysis obtained 20 biological processes, mainly involved in positive regulation of transcription from RNA polymerase II promoter, Apoptotic process, positive regulation of ERK1 and ERK2 cascade, Epithelial cell proliferation and smooth muscle cell proliferation, etc. Conclusion This study preliminarily revealed the pharmacodynamic substance basis of Maxing Shigan Decoction and its possible mechanisms for treating bronchial asthma, providing reference for the study of Maxing Shigan decoction in the treatment of bronchial asthma.

R285.5

河南省自然科學(xué)基金資助項(xiàng)目（182300410310）